USFDA Launches Operation TrialBlazer to Accelerate Drug Development and Clinical Trials
Bengaluru: The U.S. Food and Drug Administration said on Monday it is launching a series of measures to speed up drug research, from early-stage investigational studies to late-stage trials, under an initiative called Operation TrialBlazer.
The FDA said it is planning a new pilot program that would pair drug sponsors with qualified research institutions such as academic medical centers and contract research organizations to shorten the time from drug identification to first-in-human studies.
It separately updated its guidance for early-stage studies, saying a more phase-appropriate approach could save companies six to 12 months of development time.
In late-stage development, drugmakers may be able to rely on one rigorous, well-controlled pivotal trial plus confirmatory evidence, rather than multiple pivotal studies, for approval.
The agency also launched a webpage to bring together regulatory requirements, guidance and examples in one place, aimed in part at helping smaller companies.
It said a new Phase 1 Contact Center will provide real-time answers on protocols, regulatory requirements and other early-trial questions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.